Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Pancreatic cancer

Platelet derived growth factor receptor B (PDGFRB; PDGFR1; CD140B)

Studies in mice and human samples suggest inhibiting PDGFRB could help prevent pancreatic cancer metastasis. In mice injected with metastasis-prone pancreatic cancer cells, shRNA knockdown or pharmacological inhibition of Pdgfrb with crenolanib or Gleevec imatinib decreased metastatic spread compared with no alteration or inhibition. In human pancreatic ductal adenocarcinoma samples, elevated levels PDGFRB correlated with poor disease-free survival and decreased time to relapse. Next steps could include evaluating pharmacological PDGFRB inhibitors in additional pancreatic cancer models.
Novartis AG markets Gleevec, a BCR-ABL tyrosine kinase inhibitor, to treat chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and gastrointestinal stromal tumors (GISTs).
Arog Pharmaceuticals LLC's crenolanib is in Phase II testing to treat acute myelogenous leukemia (AML) and Phase I to treat brain cancer.

SciBX 7(18); doi:10.1038/scibx.2014.524
Published online May 8, 2014

Patent and licensing status unavailable

Weissmueller, S. et al. Cell; published online April 10, 2014;
doi:10.1016/j.cell.2014.01.066
Contact: Scott W. Lowe, Memorial Sloan Kettering Cancer Center,
New York, N.Y.
e-mail:

lowes@mskcc.org